|
1
|
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
|
J Clin Oncol
|
2006
|
11.26
|
|
2
|
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
|
J Clin Oncol
|
2011
|
7.24
|
|
3
|
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
|
Cancer
|
2006
|
5.03
|
|
4
|
Recommendations on the use of 18F-FDG PET in oncology.
|
J Nucl Med
|
2008
|
4.71
|
|
5
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
6
|
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
|
J Clin Oncol
|
2012
|
4.42
|
|
7
|
Development and validation of a predictive model for chemotherapy-associated thrombosis.
|
Blood
|
2008
|
4.06
|
|
8
|
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
|
J Clin Oncol
|
2007
|
4.06
|
|
9
|
American Society of Clinical Oncology 2013 top five list in oncology.
|
J Clin Oncol
|
2013
|
4.03
|
|
10
|
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.
|
Cancer
|
2006
|
3.86
|
|
11
|
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.
|
Cancer
|
2007
|
3.27
|
|
12
|
Retracted
Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
|
JAMA
|
2008
|
3.26
|
|
13
|
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
|
Cancer
|
2004
|
3.15
|
|
14
|
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
|
J Clin Oncol
|
2011
|
2.76
|
|
15
|
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
|
J Natl Compr Canc Netw
|
2011
|
2.73
|
|
16
|
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score.
|
Cancer
|
2011
|
2.67
|
|
17
|
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
|
Am J Manag Care
|
2005
|
2.37
|
|
18
|
Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
|
Cancer
|
2009
|
2.35
|
|
19
|
Undertreatment of obese women receiving breast cancer chemotherapy.
|
Arch Intern Med
|
2005
|
2.25
|
|
20
|
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.
|
Cancer
|
2005
|
2.20
|
|
21
|
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.
|
J Clin Oncol
|
2006
|
2.17
|
|
22
|
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
|
J Clin Oncol
|
2005
|
2.13
|
|
23
|
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients.
|
Transfusion
|
2007
|
2.12
|
|
24
|
Thromboembolism in hospitalized neutropenic cancer patients.
|
J Clin Oncol
|
2006
|
2.03
|
|
25
|
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.
|
J Clin Oncol
|
2012
|
2.02
|
|
26
|
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
|
J Clin Oncol
|
2007
|
1.92
|
|
27
|
Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.
|
Arch Intern Med
|
2008
|
1.85
|
|
28
|
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.
|
J Clin Oncol
|
2008
|
1.75
|
|
29
|
Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy.
|
Thromb Res
|
2010
|
1.66
|
|
30
|
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
|
J Natl Compr Canc Netw
|
2008
|
1.65
|
|
31
|
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.
|
Ann Surg Oncol
|
2012
|
1.56
|
|
32
|
A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.
|
Cancer
|
2007
|
1.54
|
|
33
|
Variation in the cost of medications for the treatment of colorectal cancer.
|
Am J Manag Care
|
2008
|
1.39
|
|
34
|
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.
|
Genet Med
|
2012
|
1.39
|
|
35
|
Length of stay and mortality associated with febrile neutropenia among children with cancer.
|
J Clin Oncol
|
2005
|
1.38
|
|
36
|
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.
|
J Clin Oncol
|
2008
|
1.27
|
|
37
|
Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.
|
Ann Intern Med
|
2014
|
1.27
|
|
38
|
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2006
|
1.25
|
|
39
|
Undertreatment of cancer patients with chemotherapy is a global concern.
|
J Oncol Pract
|
2008
|
1.23
|
|
40
|
Myeloid growth factors. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2007
|
1.23
|
|
41
|
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.
|
J Clin Oncol
|
2009
|
1.21
|
|
42
|
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches.
|
Support Care Cancer
|
2004
|
1.16
|
|
43
|
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
|
Value Health
|
2008
|
1.14
|
|
44
|
Biosimilars: are they ready for primetime in the United States?
|
J Natl Compr Canc Netw
|
2011
|
1.14
|
|
45
|
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.
|
J Natl Compr Canc Netw
|
2003
|
1.14
|
|
46
|
Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline.
|
J Clin Oncol
|
2014
|
1.13
|
|
47
|
Myeloid growth factors.
|
J Natl Compr Canc Netw
|
2013
|
1.13
|
|
48
|
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology.
|
J Clin Oncol
|
2012
|
1.12
|
|
49
|
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis.
|
J Clin Oncol
|
2011
|
1.12
|
|
50
|
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
|
Cancer
|
2007
|
1.11
|
|
51
|
ASCO Clinical Practice Guidelines: Past, Present and Future.
|
J Oncol Pract
|
2008
|
1.10
|
|
52
|
Costs associated with febrile neutropenia in the US.
|
Pharmacoeconomics
|
2012
|
1.06
|
|
53
|
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
|
Gynecol Oncol
|
2012
|
1.04
|
|
54
|
Myeloid growth factors.
|
J Natl Compr Canc Netw
|
2011
|
1.03
|
|
55
|
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.
|
Cancer Med
|
2014
|
1.03
|
|
56
|
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.
|
Genet Med
|
2012
|
1.03
|
|
57
|
Antiemetics: american society of clinical oncology clinical practice guideline update.
|
J Oncol Pract
|
2011
|
1.02
|
|
58
|
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
|
Cancer
|
2009
|
1.02
|
|
59
|
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.
|
J Natl Cancer Inst
|
2013
|
0.98
|
|
60
|
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
|
J Natl Compr Canc Netw
|
2008
|
0.96
|
|
61
|
Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.
|
Breast Cancer Res Treat
|
2012
|
0.96
|
|
62
|
Breast cancer screening with mammography.
|
Curr Oncol Rep
|
2011
|
0.95
|
|
63
|
Myeloid growth factors.
|
J Natl Compr Canc Netw
|
2009
|
0.94
|
|
64
|
Venous thromboembolism in patients with diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2006
|
0.93
|
|
65
|
Hemopoiesis and aging.
|
Cancer Treat Res
|
2005
|
0.93
|
|
66
|
Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
|
J Oncol Pharm Pract
|
2013
|
0.93
|
|
67
|
Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.
|
Crit Rev Oncol Hematol
|
2009
|
0.92
|
|
68
|
The colony-stimulating factors: use to prevent and treat neutropenia and its complications.
|
Expert Opin Biol Ther
|
2004
|
0.90
|
|
69
|
Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest.
|
J Thorac Oncol
|
2011
|
0.90
|
|
70
|
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
|
Value Health
|
2008
|
0.89
|
|
71
|
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
|
J Natl Cancer Inst
|
2011
|
0.89
|
|
72
|
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
|
Gynecol Oncol
|
2012
|
0.88
|
|
73
|
Time is money for both the healthy and the sick.
|
Med Care
|
2005
|
0.88
|
|
74
|
Sentinel node biopsy for head and neck melanoma: a systematic review.
|
Otolaryngol Head Neck Surg
|
2011
|
0.87
|
|
75
|
Will biosimilars gain momentum?
|
J Natl Compr Canc Netw
|
2013
|
0.87
|
|
76
|
A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
|
Value Health
|
2012
|
0.87
|
|
77
|
Ductal carcinoma in situ: a review of recent advances.
|
Curr Opin Obstet Gynecol
|
2007
|
0.87
|
|
78
|
Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
|
Med Care
|
2011
|
0.87
|
|
79
|
Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients.
|
Breast Cancer Res Treat
|
2011
|
0.87
|
|
80
|
Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
|
Cancer Invest
|
2009
|
0.86
|
|
81
|
Screening mammography at 40-49 years: regret or no regret?
|
Lancet
|
2006
|
0.86
|
|
82
|
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
|
Am J Med
|
2004
|
0.85
|
|
83
|
Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.
|
Cancer Treat Rev
|
2006
|
0.85
|
|
84
|
Availability of experimental therapy outside oncology randomized clinical trials in the United States.
|
J Clin Oncol
|
2010
|
0.85
|
|
85
|
Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines?
|
J Oncol Pract
|
2011
|
0.85
|
|
86
|
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
|
J Hematol Oncol
|
2010
|
0.84
|
|
87
|
Short-term costs associated with primary prophylactic G-CSF use during chemotherapy.
|
Am J Manag Care
|
2013
|
0.84
|
|
88
|
ASCO Clinical Practice Guidelines and Beyond.
|
J Oncol Pract
|
2007
|
0.84
|
|
89
|
Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
|
J Med Econ
|
2013
|
0.83
|
|
90
|
Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.
|
Breast Cancer Res Treat
|
2010
|
0.82
|
|
91
|
The impact of anaemia and its treatment on employee disability and medical costs.
|
Pharmacoeconomics
|
2005
|
0.82
|
|
92
|
Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
|
Crit Rev Oncol Hematol
|
2013
|
0.81
|
|
93
|
Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
|
Cancer
|
2012
|
0.81
|
|
94
|
Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines.
|
J Oncol Pract
|
2011
|
0.81
|
|
95
|
Myeloid growth factors clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2005
|
0.80
|
|
96
|
Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry.
|
J Support Oncol
|
2005
|
0.80
|
|
97
|
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
|
Pharmacoeconomics
|
2012
|
0.79
|
|
98
|
Burden of pancreatic cancer and disease progression: economic analysis in the US.
|
Oncology
|
2006
|
0.79
|
|
99
|
Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature.
|
Support Cancer Ther
|
2004
|
0.79
|
|
100
|
Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
|
Pharmacoeconomics
|
2012
|
0.78
|
|
101
|
Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
|
Value Health
|
2005
|
0.78
|
|
102
|
Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.
|
Support Care Cancer
|
2014
|
0.78
|
|
103
|
Preventing VTE in Outpatients With Cancer.
|
Chest
|
2012
|
0.78
|
|
104
|
The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study.
|
BMC Nurs
|
2003
|
0.77
|
|
105
|
Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer.
|
Cancer Invest
|
2009
|
0.77
|
|
106
|
Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
|
Pharmacotherapy
|
2004
|
0.77
|
|
107
|
G-CSF as prophylaxis of febrile neutropenia in SCLC.
|
Expert Opin Pharmacother
|
2002
|
0.77
|
|
108
|
Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.
|
Cancer
|
2013
|
0.77
|
|
109
|
Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
|
Pharmacoeconomics
|
2007
|
0.77
|
|
110
|
Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.
|
JAMA
|
2012
|
0.77
|
|
111
|
Economic implications of 21-gene recurrence score assay: US multicenter experience.
|
J Clin Oncol
|
2010
|
0.77
|
|
112
|
Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
|
J Clin Oncol
|
2012
|
0.76
|
|
113
|
Caring for the elderly cancer patient: training the next generation of oncologists.
|
J Oncol Pract
|
2008
|
0.76
|
|
114
|
Editorial: gene expression profile assays as an aid in treatment decision making in early-stage breast cancer.
|
J Oncol Pract
|
2007
|
0.75
|
|
115
|
Withholding antibiotics from patients with febrile neutropenia.
|
J Clin Oncol
|
2006
|
0.75
|
|
116
|
Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.
|
J Natl Cancer Inst
|
2009
|
0.75
|
|
117
|
Isolated tumor cells in breast cancer.
|
N Engl J Med
|
2009
|
0.75
|
|
118
|
Use of antibiotics and risk of cancer.
|
JAMA
|
2004
|
0.75
|
|
119
|
Preventing venous thromboembolism in cancer patients: can we do better?
|
J Oncol Pract
|
2009
|
0.75
|
|
120
|
Journal of oncology practice in transition.
|
J Oncol Pract
|
2008
|
0.75
|
|
121
|
Use of re-randomized data in meta-analysis.
|
BMC Med Res Methodol
|
2005
|
0.75
|
|
122
|
Economics of cancer care.
|
J Oncol Pract
|
2007
|
0.75
|
|
123
|
Estimating net benefits and harms of screening mammography in women age 40 to 49 years.
|
Ann Intern Med
|
2007
|
0.75
|
|
124
|
Introduction. Neutropenia risk models in oncology.
|
Oncology (Williston Park)
|
2003
|
0.75
|
|
125
|
Agents under investigation for the treatment and prevention of neutropenia.
|
Expert Opin Investig Drugs
|
2007
|
0.75
|
|
126
|
Prophylactic pegfilgrastim significantly reduces febrile neutropenia during moderately myelosuppressive chemotherapy.
|
Support Cancer Ther
|
2004
|
0.75
|
|
127
|
Prevalence and impact of correlative science in breast cancer phase II trials.
|
Breast Cancer Res Treat
|
2013
|
0.75
|
|
128
|
Statement of retraction: Hongying Lv, Qicai Li, Wengsheng Qiu, Jinyu Xiang, Hongjun Wei, Hua Liang, Aihua Sui and Jun Liang "Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer".
|
Cancer Invest
|
2013
|
0.75
|
|
129
|
Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.
|
Breast Cancer Res Treat
|
2009
|
0.75
|
|
130
|
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
|
Thromb Haemost
|
2017
|
0.75
|
|
131
|
The economics of the hematopoietic growth factors.
|
Cancer Treat Res
|
2011
|
0.75
|
|
132
|
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|